DOCSLIB.ORG

API (Active Pharmaceutical Ingredient)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
API (Active Pharmaceutical Ingredient) API (active pharmaceutical ingredient): # C DIHYDROXYDIBUTYLETHER 6- APA (6-amino-penicillanic acid) CALCIUM DOBESILATE DIISOPROPYLAMINE DICHLOROACETATE 7-ADCA (7-amino-deacetoxycephalosporanic acid) CALCIUM PHOSPHORYLCOLINE DILTIAZEM HCL CALCIUM PHOSPHORYLCOLINE CHLORIDE DILTIAZEN HYDROCHLORIDE A CARBAMAZEPINE DIMENHYDRINATE DIPHENHYDRAMINE CITRATE ACEBUTOLOL CARBOCISTEINE DIPHENHYDRAMINE HCL ACETAZOLAMIDE CARISOPRODOL DIPYRIDAMOLE ACYCLOVIR CARTEOLOL DISODIUM CLODRONATE ADENOSINE CARTEOLOL HYDROCHLORIDE DISODIUM CROMOGLICATE ALLOPURINOL CARVEDILOL DISOPYRAMIDE BASE AND PHOSPHATE AMBROXOL CASPOFUNGINA ACETATO D-L CLOPERASTINE FENDIZOATE AMILORIDE CEFACLOR D-L CLOPERASTINE HCL AMILORIDE HCL CEFADROXIL MONOHYDRATE D-L DROPROPIZINE AMITRIPTYLINE HCL CEPHALEXIN MONOHYDRATE DOBUTAMINE HCL AMOXICILLIN ANHYDROUS CETIRIZINE 2HCL DOCUSATE SODIUM (compacted and powder) CETRIMIDE DOPAMINE HCL AMOXICILLIN TRIHYDRATE CHLORDIAZEPOXIDE (compacted and powder) CHLORDIAZEPOXIDE HYDROCHLORIDE AMPICILLIN TRIHYDRATE CHLORMEZANONE E (compacted and powder) CHLORPHENIRAMINE MALEATE ENTACAPONE ANAGRELIDE CHLORPROMAZINE HCL ERYTHROMYCIN BASE ANTAZOLINE SULPHATE CHLORTHALIDONE ERYTHROMYCIN ESTOLATE ANTAZOLYNE HCL CHYMOTRYSIN ERYTHROMYCIN ETHYL SUCCINATE ARTICAINE HCL CIMETIDINE ERYTHROMYCIN OXIME (intermediate) ARTEETHER CITALOPRAM ERYTHROMYCIN SALTS ARTESUNATE CITICOLINE ERYTHROMYCIN STEARATE ASPARTAME CLARITHROMYCIN ESTAZOLAM ATENOLOL CLAVULANATO POTASSIO ETHAMBUTOL 2 HCL ATORVASTATIN (avicel and siloire) ETHANOL-2-AMINO PHOSPHORIC ACID AZITHROMYCIN CLAVULANATO POTASSIO STERILE ETHIONAMIDE CLIDINIUM BROMIDE ETODOLAC B CLOBAZAM CLODRONATE DISODIUM BACLOFEN F CLOMIFENE CITRATE BENIDIPINE FENOTEROL CLOMIPRAMINE HCL BENIDIPINE HCL FENOTEROL HYDROBROMIDE CLONAZEPAM BENZHEXOL HCL (TRIHEXYPHENYDIL HCL) FENSPIRIDE CLONIDINE BASE BENZYDAMINE HCL FEXOFENADINE CLONIDINE HCL BETAHISTINE 2HCL FLECAINIDE ACETATE CLOPAMIDE BETAINE HCL FLUCLOZACILLIN SODIUM CLOTRIMAZOLE BETAXOLOL HYDROCHLORIDE (compacted and powder) CLOXACILLIN SODIUM (compacted and powder) BICALUTAMIDE FLUCYTOSINE CYPROHEPTADINE HCL BIFEMELANE FLUFENAMIC ACID BISACODYL (PHENYLAX) FLUNARIZINE DIHYDRICHLORIDE BROMAZEPAM D FLUNITRAZEPAM BROMHEXINE HCL DELOEAZEPAM FLUOROMETHOLONE BROMOPRIDE DEQUALINIUM CHLORIDE FLUOXETINE HCL BUFEXAMAC DEXTROMETORPHAN HYDROBROMIDE FLUPHENAZINE DECANOATE BUFLOMEDIL HCL DIAVERIDINE HCL FLURAZEPAM BUPIVACAINE HCL DIAZEPAM FLURAZEPAM DIHYDROCHLORIDE DICLOFENAC SODIUM FLURAZEPAM HYDROCHLORIDE DICLOXACILLIN (compacted and powder) FLUTAMIDE DIHYDROARTEMISININ FORMOTEROL FUMARATE NOTE: The aforementioned products shall not be used in any country where such products are covered by patents other than for research and development purposes, in compliance with applicable laws and regulations, including Article 10.6 of Directive 2001/83/EC and corresponding national provisions. NOTA: Os produtos acima referidos só poderão ser utilizados para fins de pesquisa e desenvolvimento em todos os países em que estejam sob protecção de patente, de acordo com as leis e regulamentos em vigor, incluindo o artigo 10.6 da Directiva 2001/83/CE e respectiva legislação nacional 1/3 API (active pharmaceutical ingredient): FOSPHENYTOIN M ORPHENADRINE HCL FUROSEMIDE MANIDIPINE OXACILLIN SODIUM (compacted and powder) MANIDIPINE DIHYDROCHLORIDE OXANTEL PAMOATE G MEBENDAZOLE POLYMORPH “C” OXAPROZIN GEMFIBROZIL MEBENDAZOLE USP WHITE OXAZEPAM GLIBENCLAMIDE MEBEVERINE HCL OXCARBAZEPINE GLICAZIDE MEFENAMIC ACID OXOLAMINE CITRATE AND PHOSPHATE GLIPIZIDE MELOXICAM OXYMETHOLONE GLYCOFUROL (TETRAGLYCOL) MEMANTINE GLYCOPYRROLATE MEMANTINE HCL / BASE P MEPENZOLATE BROMIDE PAMOIC ACID/SODIUM PAMOATE H MEPIFILLINE PANCREATIN HALOPERIDOL MEPIVACAINE HCL PANTETHINE 80% HYDROCHLOROTHIAZIDE MESALAZINE PAPAVERINE HCL HYDROXYZINE 2HCL / PAMOATE METFORMIN PENICILLIN G POTASSIUM, NON STERILE HYDROXYZINE HCL / PAMOATE METFORMIN HCL PENICILLIN G PROCAINE, NON STERILE METHYLTHIOURACIL PENTAZOCINE METOCLOPRAMIDE PENTAZOCINE HYDROCHLORIDE I METOCLOPRAMIDE BASE / HCL / 2HCL PHENFORMIN HYDROCHLORIDE IBUPROFEN LYSINATE METOPROLOL SUCCINATE PHENYTOIN IMIPRAMINE HCL METOPROLOL TARTRATE PHENYTOIN SODIUM INDAPAMIDE MIANSERINA HCL PHOSPHOCREATINE SODIUM INDOMETHACIN MICAFUNGIN PHOSPHORYLCOLAMINE INDORAMIN HYDROCHLORIDE MICONAZOLE BASE-NITRATE PINDOLOL IPRATROPIUM BROMIDE MINOXIDIL PIPEMIDIC ACID IRBESARTAN MORANTEL CITRATE AND TARTRATE PIPENZOLATE METHYLBROMIDE ISOCONAZOLE NITRATE MOXIFLOXACIN PIRACETAM ISONIAZID PIROXICAM ISOXSUPRINE HCL N PIZOTIFEN MALATE ITRACONAZOLE NALIDIXIC ACID PRAZOSIN NATEGLINIDE PRENOXIDIAZINE K NEOMYCIN SULPHATE PRENOXIDIAZINE HIBENZOATE PRIDINOL MESYLATE KETAZOLAM NICARDIPINE HYDROCHLORIDE PROCETOFEN KETOPROFEN NICLOSAMIDE PROCLORPERAZINE MALEATE KETOPROFEN LYSINATE NIFEDIPINE HCL PROMETHAZINE HCL KETOROLAC NIMESULIDE PROPRANOLOL HCL KETOTIFEN FUMARATE NIMODIPINE NISOLDIPINE PYRANTEL PAMOATE NITRAZEPAM PYRANTEL PAMOATE /TARTRATE L NITRENDIPINE PYRANTEL TARTRATE LABETALOL HCL NITROFURANTOIN MONOHYDRATE PYRAZINAMIDE LACTULOSE 50% NITROFURANTOIN (regular or macro crystals) PYRIDOXAL-5-PHOSPHATE LANZOPRAZOLE NITROXOLINE PYRISUCCIDEANOL DIMALEATE LEFLUNOMIDE NONOXYNOL 9 PYRITHIOXINE HCL OR PYRITINOL HCL LIDOCAINE BASE NYLIDRINE HCL (BUPHENINE HCL) LIDOCAINE HCL NYSTATIN Q LOPERAMIDE NYSTATIN CRUDE (MYCELIUM) QUETIAPINE FUMARATE LORAZEPAM NYSTATIN POWDER LOSARTAN POTASSIUM LUMEFANTRINE R LYSINE ACETYLSALICYLATE O RANITIDINE FORM 1+ FORM 2 ORCIPRENALINE SULFATE RANOLAZINE ORPHENADRINE CITRATE REPROTEROL HYDROCHLORIDE NOTE: The aforementioned products shall not be used in any country where such products are covered by patents other than for research and development purposes, in compliance with applicable laws and regulations, including Article 10.6 of Directive 2001/83/EC and corresponding national provisions. NOTA: Os produtos acima referidos só poderão ser utilizados para fins de pesquisa e desenvolvimento em todos os países em que estejam sob protecção de patente, de acordo com as leis e regulamentos em vigor, incluindo o artigo 10.6 da Directiva 2001/83/CE e respectiva legislação nacional 2/3 API (active pharmaceutical ingredient): RITODRINE HYDROCHLORIDE Z ROLITETRACYCLINE ZALTROPROFENE ROSUVASTATIN ZEAXANTINE ROSUVASTATIN CALCIUM ZIDOVIDINE ZOPICLONE S SACCHARINS SALBUTAMOL BASE AND SULPHATE SERTRALINE HCL SILVER SULPHADIAZINE SOTALOL HCL SPIRONOLACTONE STANAZOLOL SUCRALFATE SULFINPYRAZONE SULPIRIDE T TELMISARTAN TEMAZEPAN TERAZOSIN HCL 2H2O TERBUTALINE SULFATE TETRABENAZINE TETRAHYDROZOLINE HCL TETRAZEPAM THEOPHYLLINE ETHYLENDIAMINE THIABENDAZOLE THIOCTIC ACID THIORIDAZINE BASE AND HCL TIAPRIDE TICLOPIDINE TICLOPIDINE HCL TIRATRICOL (TRIAC) TOLAZAMIDE TOLMETIN SODIUM TOLNAFTATE TORASEMIDA TRAMADOL TRIBENOSIDE TRICHLORMETHIAZIDE TRICLABENDAZOLE TRIFLUOPERAZINE HCL TRIMEBUTINE MALEATE TRIPROLIDINE TROXERUTIN TYLOSIN TARTRATE V VERALIPRIDA VERAPAMIL HCL VIDARABINA VINCAMINA BASE NOTE: The aforementioned products shall not be used in any country where such products are covered by patents other than for research and development purposes, in compliance with applicable laws and regulations, including Article 10.6 of Directive 2001/83/EC and corresponding national provisions. NOTA: Os produtos acima referidos só poderão ser utilizados para fins de pesquisa e desenvolvimento em todos os países em que estejam sob protecção de patente, de acordo com as leis e regulamentos em vigor, incluindo o artigo 10.6 da Directiva 2001/83/CE e respectiva legislação nacional 3/3.
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors
    저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population.
    [Show full text]
  • Elif Fatma Sen BW.Indd
    Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • User's Manual for the SABE Databases
    User's Manual for the SABE Databases Pan American Health Organization ,.. , ) '· ~~'-~ l!c, , ~0//,rr olthe •! · 0 World Hea lth Organization ' Washington, D.C. September 2004 The user's manual for the SABE survey databases was prepared by the SABE regional coordination team of the Pan American Health Organization, Washington, DC, August 2004. International teams responsible for the survey in each of the seven cities provided technical support for the preparation and review of this document. Comments, questions, or requests for information can be directed to Martha Pelaez at [email protected] 2 TABLE OF CONTENTS INTRODUCTION .................................... ........................... ..... ............... ... .......... ... 4 PRINCIPAL SABE SURVEY RESEARCHERS ... ............ .... ................................................. 6 DESIGN OF THE SAMPLE ...................... .............................. .. .......... ............... .. 7 DIRECT, PROXY, AND ASSISTED INTERVIEWS ......... .......................... .. ..... .. .. ............. ... 15 SECTION A: GENERAL DATA .................................... ... .. ................... ...... ............ ... 16. Identification of the Gender of the Interviewee A3 Classification and Code: Birthplace A11a Religion A12 Ethnic Group A 13 History of Relationships and Marital Status SECTION 8: COGNITIVE STATUS ......... .. .. ............. .. ..... .. .. .. ·-· ......................... ...... ... .20 Mini Mental State Examination (MMSE) Pfeffer SECTION C: HEALTH STATUS .... ...................
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Australian Statistics on Medicines 1999–2000
    Commonwealth Department of Health and Ageing Australian Statistics on Medicines 1999–2000 © Commonwealth of Australia 2003 ISBN 0 642 82184 4 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth available from AusInfo. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra ACT 2601. Publications Approval Number: 3183 (PA7270) FOREWORD Comprehensive and valid statistics on use of medicines by Australians in the public domain should be accessible to all interested parties. From the first edition in 1992 until 1999 the Drug Utilisation SubCommittee (DUSC) produced the Australian Statistics on Medicines (ASM) for each calendar year to 1998. It is pleasing indeed to be able to present these again this year, with the inclusion of estimates for the years since the last edition. A continuous data set representing estimates of the aggregate community use (non public hospital) of prescription medicines in Australia is a key tool for the Australian Medicines Policy. The ASM presents dispensing data on most drugs marketed in Australia and is the only current source of data in Australia to cover all prescription medicines dispensed in the community. Drug utilisation data can assist the targeting and evaluation of quality use of medicines initiatives, and the evaluation of changes to the availability of medicines. It is also needed for pharmacosurveillance by regulatory and financing authorities and by the Pharmaceutical Industry. Publication of the Australian data also facilitates international comparisons of drug utilisation profiles and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]